SCHEMBL3154115

SCHEMBL3154115

O=C(c1ccc(S(=O)(=O)Nc2nccs2)cc1)N(Cc1ccccc1)[C@@H](CO)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 5/20 0.58
SCN1A P35498 4/20 0.53
SCN5A Q14524 4/20 0.53
SCN8A Q9UQD0 4/20 0.53
SCN4A P35499 1/20 0.53
SCN9A Q15858 1/20 0.53
SCN2A Q99250 1/20 0.53
SCN10A Q9Y5Y9 1/20 0.53
PKM P14618 1/20 0.52
SCN1B Q07699 2/20 0.51
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 1/20 0.46
CA1 P00915 1/20 0.46
CYP3A4 P08684 1/20 0.46
PTGS1 P23219 1/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3158611 0.90 SCN1A (0.56) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3162519 0.88 SCN3A (0.63) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3165520 0.82 SCN3A (0.59) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3165535 0.80 SCN8A (0.54) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3162710 0.77 LIMK2 (0.70) SCN3APKMMEN1KMT2AALDH1A1
SCHEMBL3168368 0.77 LIMK2 (0.67) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3168815 0.77 SCN3A (0.64) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3166893 0.76 SCN8A (0.56) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3163253 0.76 SCN8A (0.56) SCN3ASCN1ASCN5ASCN8ASCN4A
SCHEMBL3163245 0.76 SCN8A (0.56) SCN3ASCN1ASCN5ASCN8ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN1A 6/4885SCN5A 15/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN1A 6/4885SCN5A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.